Valuation: Norda ASA

Market Cap 513M 54.11M 46.84M 43.78M 40.02M 75.41M 5.16B 76.59M 513M 201M 2.58B 203M 199M 8.6B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 27.87M 24.13M 22.55M 20.61M 38.84M 2.66B 39.45M 264M 104M 1.33B 105M 102M 4.43B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
3 months+1.53%
6 months+1.53%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 2013-04-07
Director TitleAgeSince
Director/Board Member 68 2013-06-19
Chairman 54 2014-01-30
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+7.87%+110.73% 46.75M
-0.71%+3.46%+6.43%+16.36% 50.03B
+0.89%+13.44%+491.34%+594.30% 44.36B
+3.08%+14.42%+24.57%+81.39% 40.82B
+1.38%+3.70%+34.54%+9.11% 39.83B
+0.85%+10.32%+21.22%+47.64% 32.51B
+0.08%+5.00% - - 16.85B
+1.99%+5.08%+38.70%+125.08% 16.81B
-0.09%+3.40%+5.39%+18.79% 14.05B
+3.56%+19.98%+86.23%+27.29% 13.22B
Average +1.50%+6.74%+79.59%+114.52% 26.85B
Weighted average by Cap. +1.49%+7.09%+107.49%+139.66%

Financials

2023 2024
Net sales 86.92M 9.17M 7.93M 7.42M 6.78M 12.77M 874M 12.97M 86.97M 34.12M 437M 34.41M 33.66M 1.46B 372M 39.21M 33.94M 31.73M 29M 54.64M 3.74B 55.5M 372M 146M 1.87B 147M 144M 6.23B
Net income 31.17M 3.29M 2.85M 2.66M 2.43M 4.58M 313M 4.65M 31.19M 12.24M 157M 12.34M 12.07M 522M 126M 13.28M 11.5M 10.75M 9.82M 18.51M 1.27B 18.8M 126M 49.45M 634M 49.86M 48.78M 2.11B
Net Debt -311M -32.82M -28.41M -26.56M -24.27M -45.74M -3.13B -46.45M -311M -122M -1.57B -123M -121M -5.22B -249M -26.24M -22.71M -21.23M -19.4M -36.56M -2.5B -37.13M -249M -97.68M -1.25B -98.51M -96.36M -4.17B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock